On November 10, Clorox rose 5.11% in Regular Trading, trading at $105.1 per share, with turnover of $169 million.

The move was supported by the company’s latest quarterly results coming in ahead of expectations, followed by several institutions lifting price targets after the report.

Clorox reported fiscal first-quarter adjusted EPS of $1.55, well above the $1.07 consensus estimate, while revenue reached $1.905 billion versus the expected $1.876 billion. The company also reiterated fiscal 2027 guidance, though it said adjusted EPS is likely to land near the low end of the $5.70 to $6.00 range as cost pressures persist.

After the release, multiple brokers raised target prices, including BNP Paribas to $98 from $89 and Deutsche Bank to $99 from $95, while Evercore ISI had earlier upgraded the stock to in line with a $99 target. Even so, several analyst notes continued to describe the overall stance as broadly hold or balanced given inflation, margin pressure and uncertainty around the durability of sales growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)